Atomo Diagnostics, Sydney, and Access Bio Inc, Somerset, NJ, have announced a strategic partnership to leverage their respective strengths in rapid diagnostics to expand point-of-care human immunodeficiency virus (HIV) testing in global markets.

Atomo will supply its AtomoRapid lateral-flow diagnostic platform for use with Access Bio’s in vitro HIV rapid test, which detects the presence of HIV antibodies in a single drop of blood obtained from a fingertip. The test result can be read in minutes, which is essential for same-day diagnosis, early treatment, and care.

The new test will be commercialized under Access Bio’s CareStart brand for professional use markets in territories across Africa, Commonwealth of Independent States countries, South America, and South East Asia.

Dedicated to the prevention and early diagnosis of infectious diseases, Access Bio and its subsidiary, Wells Bio Inc, manufacture more than 120 million rapid diagnostic tests annually for the detection of a range of infectious diseases, including dengue, HIV, and malaria. The new partnership with Atomo Diagnostics will strengthen Access Bio’s rapid test portfolio and support continued growth.

“Access Bio is delighted to announce our new strategic partnership with Atomo Diagnostics, which will add to and enhance our existing rapid test range,” says Young Ho Choi, chief executive and founder of Access Bio. “Atomo’s all-in-one test devices, which simplify and standardize test procedures, will help us improve the performance and user-friendliness of our HIV test for our customers. Access Bio’s HIV test strips combined with Atomo’s test devices will also offer an innovative solution to support the HIV 90-90-90 campaign.”

John Kelly, Atomo Diagnostics.

John Kelly, Atomo Diagnostics.

“We are excited about this commercial partnership with Access Bio, a recognized market leader in rapid diagnostic testing,” says John Kelly, founder and CEO of Atomo Diagnostics. “Our AtomoRapid platforms are proving their excellent usability and performance for a range of applications internationally, and this new partnership adds significantly to our long-term growth plans. Moreover, it demonstrates our continued commitment to tackling HIV by enabling greater access to best-in-class diagnostics in areas hardest hit by the disease.”

For more information, visit Access Bio and Atomo Diagnostics.